Biomea Fusion, Inc.
A clinical-stage biopharmaceutical company that designs oral covalent small molecule drugs to treat diabetes and obesity. Its lead candidate, icovamenib, forms a permanent bond with a protein called menin to help the body regenerate its own insulin-producing beta cells. Founded in 2017 by Thomas Butler in Redwood City, California, the name "Biomea" blends the Greek word for life ("bios") with the Latin word for "my," reflecting the mission to improve the life of each patient.
Bought 80.0K
Bought 110.0K
Granted 6.3K · Bought 12.5K
Granted 349
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Erdtmann Rainer MSee Remarks, Director · 23 transactions | — | 3.20M | — | 80.0K | — |
| Hitchcock Michael J.M.Interim CEO, Director · 2 transactions | +2200% | 115.0K | — | 110.0K | — |
| Valle FrancoChief Financial Officer · 4 transactions | +77.7% | 43.0Kas of Nov 2024 | 6.3K | 12.5K | — |
| Frias Juan PabloChief Medical Officer · 1 transaction | — | 349as of May 2024 | 349 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +202.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.